{"name":"Connect Biopharma","slug":"connect-biopharma","ticker":"CNTB","exchange":"NASDAQ","domain":"connectbiopharm.com","description":"Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.","hq":"San Diego, CA / Taicang, China","founded":0,"employees":"64","ceo":"Zheng Wei","sector":"Dermatology / Immunology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":2.57,"stockChange":0.12,"stockChangePercent":4.9,"marketCap":"$145M","metrics":{"revenue":26033000,"revenueGrowth":0,"grossMargin":100,"rdSpend":29256000,"netIncome":-15628000,"cash":46034000,"dividendYield":0,"peRatio":-2.3,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"CNTO 1959 patent cliff ($10.2M at risk)","drug":"CNTO 1959","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Moxifloxacin (Avelox)","genericName":"Moxifloxacin (Avelox)","slug":"moxifloxacin-avelox","indication":"Community-acquired bacterial pneumonia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CBP-307","genericName":"CBP-307","slug":"cbp-307","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Moxifloxacin (Avelox)","genericName":"Moxifloxacin (Avelox)","slug":"moxifloxacin-avelox","phase":"marketed","mechanism":"Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","indications":["Community-acquired bacterial pneumonia","Acute bacterial sinusitis","Acute bacterial exacerbation of chronic bronchitis","Uncomplicated skin and soft tissue infections","Complicated skin and soft tissue infections"],"catalyst":""},{"name":"CBP-307","genericName":"CBP-307","slug":"cbp-307","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Connect Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Connect Biopharma reported fourth quarter and full year 2023 financial results, with revenue of $10.2 million and a net loss of $23.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Connect Biopharma Announces Collaboration with Leading Dermatology Company","summary":"Connect Biopharma announced a collaboration with a leading dermatology company to develop new treatments for psoriasis and atopic dermatitis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNT2hJaWxRX0lfMW1XWURIZ1FfajZ4a2M2OWE4RF9QMW1ZY0IzeDlTUnBmSUl2TnF1N04wWUhaRk5TVGN1VWdvbGgwakdpcUJQSS1Ocm4xUEZlVVZjYWxWb1kxTVJZeHVsV3FOYUNxQTZfaXE5U19uYnRnbE80M1BFZVJDZi05M182cmRQSHA5cEMxNjBTdUhIbWZOTDRWVDJzQ0FqWUdMRWhFWHdvNmhScHlRTE5sYzdMaGhNZWZZb1FFaGg1a3hFSlpvaXJ4UnU3X0hlNXgtdGQyUDd4NHB2ak1iaklVRlphZDJxd2xmZmgySnZWN05DU1BFQkxPZldReVFpd2ZGSjRtcXg2R3hzUUNR?oc=5","date":"2026-04-07","type":"pipeline","source":"ChartMill","summary":"RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - ChartMill","headline":"RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9YLXJvSFR0ZGNTVUNMQWRaVmhpdTgzWkxIbDhTY0l5Vm16bTZ1UExESWVkdm8zWE1lRWxpTTFTY3M2bnVLT1hCSll1TXJEUzliQVB5dHFPck04WHFXaUZleFd3MA?oc=5","date":"2026-04-01","type":"pipeline","source":"TradingView","summary":"ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView","headline":"ETFs Investing in Connect Biopharma Holdings Ltd. Stocks","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1MeTlNOFBCMmRCZmRuZnhkNWZ1cEU2SXJJZkdRQUk0WWltRk5odEc2VDJ1bVl4LUJRM1puX1p2Q0dhOUFDMzJWcXgya2JxZnJCTFNlbjZOVmg4NUhuTWFCTHlOS0E2YUQyVHlUNU93?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Connect Biopharma Holdings Ltd (CNTB) - Stock Titan","headline":"If You Invested $1,000 in Connect Biopharma Holdings Ltd (CNTB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5MaVBucWpvODhWZUNXZmVuMklFZkRlck81aFRIUk05U3hVdmJSeVBXb0pVLVNtUjN2aEUwSXVXWTBnamxJRHBFS0FuTVZNdDgyRkx5eUUwODhGRE00YWdoT0hyRS13QQ?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"CNTB SEC Filings - Connect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"CNTB SEC Filings - Connect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSW01dmstQ0pRVkcwazJ0UWEwNTFVUy1kN1dIOXFjVU95Vy1TZ243M29sMmJrUXh6blZCakZWNkxBTWlwaWhRYi1Ob3BtR3FIeGIzVFNHWWEwMDhTR2pWMGcwemhMZEg1Snd6NmQxLW1pMFhRTUNhaXg3Q256aVB4bERUaEFWbTAyNk5Ja2VIRV9ESnhFNzQ1SzRXUkxTNkNqTnp5bHpiYWFDd3NoZmV4SEJjS1o1dUlBc3Zv?oc=5","date":"2026-03-10","type":"regulatory","source":"Stock Titan","summary":"Severe eczema drug from Connect Biopharma lands late-breaking AAD slot - Stock Titan","headline":"Severe eczema drug from Connect Biopharma lands late-breaking AAD slot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPVnZGYTBfR3o4czAtRFJXU1dwX190aXBvd3dCVUhxUnZXekRSeDR1TmN4ZkpHZWhVSlVBcWNVNXlXYmVQamUzWm9UR0hfY0pkaDNzV0NPdGV1aXFDREEzTGZTOUk0aEppbk9GUGs5b3R6MGdOOHR4djRLTkh2OW1Ub2t0dGh6SUV5VEctOFpOTzRHb05OSmRSVUQzRjhOOEZpZ3hfQ1hONzk0dm9xeEZqeTczSFBoWjllakRONGEzRzI1RDAxMlF6NmM3b0JYajJBWG1oU3dPczFZTkt6a3ZFeU5ER1pkZ0t6S21KVnUzVjhfRV9qRGJNb01HNkVUSVNIV0pmdEU4YU9fcGJBWmU0?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQUnIzakl6TVVrMmdCSFpUcE9pZ2N2MmNRY2ltblJSbHZ4TERfdkR1R044bnQxdEI3RW5zSUxiSEJ4T0JKeG1BYmdhS3RDTWxjMmVzYkRCWlRCZEJjWmREdzVKcHk3Z1A1b1dhY1Y5YldtWG90WHZfa0hnUGpyYnEwc3luV0lTdEE2WnpCOXRvODY0TEIzeTM3Nkk3cGs5UEpQSUpUSllzNy1RNDJVcVU2blB5dWdMbmM?oc=5","date":"2026-01-12","type":"pipeline","source":"Stock Titan","summary":"Experimental asthma and COPD drug targets rapid relief during attacks - Stock Titan","headline":"Experimental asthma and COPD drug targets rapid relief during attacks","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOY1VsZkpwak96Y1llNG04SFZibDNTUUxCQWxtTUNjODBnVjhNNXdwSU1iN2tCUDJvbV9kbjRGd0JRQ1F3RkVBR1d1UzZoS283SUoyZldvNERKU19XbDVyZ1FLNmFyTTVtLVFFSnpxSk13eXdybmpnUU9LSDhMaVB2RHdyeGtMbFI1WXJaMU1IWmNMdw?oc=5","date":"2025-12-16","type":"pipeline","source":"Yahoo Finance","summary":"Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 39% ownership, individual investors own 22% - Yahoo Finance","headline":"Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 39% ownership, ind","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-09","type":"deal","source":"globenewswire.com","summary":"Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China - globenewswi","headline":"Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Applicatio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9uSUU0OHdHRk5QdlRhR3RZUHZmMi1RRHM2U29xTExoX29JZVYtdW5PWmdzOHRyQUp0UHliOUhZTGo0SWMyV2UwRTBDam9WeUdY?oc=5","date":"2024-03-06","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxOdFdNX2lnZGdSU2NnWG5xSkdPX3dQME1DblR2bXIzeGdSa3lsbFdaTUJTaWR1WmV4ZTVqdGZzdERrWkJLS0prZjRUVmg3NmhzQlI1NmNzY0dEanBrOUhEQ09JZ1FZdE80R2d5cU5ZNDE2SHdVOWljUTdibHBQWUFvZVdCSmdlTV9xU25nQXYwdmdXV1pUNDZCZEFmWDRTUEhZOElzT2xMaGFxM2s5WEd6WjZLaUJpSVZiWldLT0Q4UlZRNWdqWFNhVHNTUDZyWnhvTi1CTFlORWhRMmNuMzg3TGJtVGdhRXE5YXE2S2xJNnRiMm94SXBKRk1Td0c2VGtHbUVnQTN3RDg3cEN6V1ZCLUt4WTJjS0dYdTRoWWg2blhpV2tCVUlwOGZ0cjJOTkJEV2E2bDRwaVNnSldJTC1zd3FFTldlZjRsN1YwaTFmYkwyaS1yejg4cTNuV0JaQTA?oc=5","date":"2021-03-23","type":"pipeline","source":"globenewswire.com","summary":"Connect Biopharma Holdings Limited Announces Closing of - globenewswire.com","headline":"Connect Biopharma Holdings Limited Announces Closing of","sentiment":"neutral"}],"patents":[{"drugName":"CNTO 1959","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10200000}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Eli Lilly and Company","Novartis"],"therapeuticFocus":["Dermatology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":26033000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":26033000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":29256000,"rdSpendHistory":[{"period":"2025-12-31","value":37798000},{"period":"2024-12-31","value":29256000},{"period":"2023-12-31","value":53002000},{"period":"2022-12-31","value":96630000}],"sgaSpend":20340000,"operatingIncome":-58074000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-58074000},{"period":"2024-12-31","value":-22452000},{"period":"2023-12-31","value":-69056000},{"period":"2022-12-31","value":-116507000}],"netIncome":-15628000,"netIncomeHistory":[{"period":"2025-12-31","value":-55480000},{"period":"2024-12-31","value":-15628000},{"period":"2023-12-31","value":-62106000},{"period":"2022-12-31","value":-118091000}],"eps":-1,"epsHistory":[{"period":"2025-12-31","value":-1},{"period":"2024-12-31","value":-0.28},{"period":"2023-12-31","value":-1.13},{"period":"2022-12-31","value":-2.101662}],"cash":38345000,"cashHistory":[{"period":"2025-12-31","value":38345000},{"period":"2024-12-31","value":78232000},{"period":"2023-12-31","value":105663000},{"period":"2022-12-31","value":79010000}],"totalAssets":101284000,"totalLiabilities":14095000,"totalDebt":690000,"equity":41980000,"operatingCashflow":-51206000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-51206000},{"period":"2024-12-31","value":-23612000},{"period":"2023-12-31","value":-47741000},{"period":"2022-12-31","value":-101520000}],"capex":-434000,"capexHistory":[{"period":"2025-12-31","value":-434000},{"period":"2024-12-31","value":-750000},{"period":"2023-12-31","value":-81000},{"period":"2022-12-31","value":-4405000}],"freeCashflow":-51640000,"dividendsPaid":null,"buybacks":0,"employees":64,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4244000,"ebit":-15526000,"ebitda":-15345000,"period":"2025-12-31","revenue":0,"epsBasic":-0.27,"netIncome":-15109000,"rdExpense":11282000,"epsDiluted":-0.27,"grossProfit":null,"operatingIncome":-15526000},{"sga":6583000,"ebit":-17677000,"ebitda":-17498000,"period":"2025-09-30","revenue":16000,"epsBasic":-0.31,"netIncome":-17200000,"rdExpense":11110000,"epsDiluted":-0.31,"grossProfit":null,"operatingIncome":-17677000},{"sga":4699000,"ebit":-13424000,"ebitda":-13253000,"period":"2025-06-30","revenue":48000,"epsBasic":-0.23,"netIncome":-12899000,"rdExpense":8773000,"epsDiluted":-0.23,"grossProfit":null,"operatingIncome":-13424000},{"sga":4814000,"ebit":-11447000,"ebitda":-11274000,"period":"2025-03-31","revenue":0,"epsBasic":-0.19,"netIncome":-10272000,"rdExpense":6633000,"epsDiluted":-0.19,"grossProfit":null,"operatingIncome":-11447000},{"sga":4081000,"ebit":-9619000,"ebitda":-9461000,"period":"2024-12-31","revenue":698000,"epsBasic":null,"netIncome":-8906000,"rdExpense":6236000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-9619000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.23,"netIncome":null,"rdExpense":null,"epsDiluted":-0.23,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.57,"previousClose":2.45,"fiftyTwoWeekHigh":3.82,"fiftyTwoWeekLow":0.7,"fiftyTwoWeekRange":"0.7 - 3.82","fiftyDayAverage":2.73,"twoHundredDayAverage":2.29,"beta":0,"enterpriseValue":108920440,"forwardPE":-2.3,"priceToBook":3.78,"priceToSales":623.43,"enterpriseToRevenue":467.47,"enterpriseToEbitda":-1.66,"pegRatio":0,"ebitda":-65539000,"ebitdaMargin":0,"freeCashflow":-34134248,"operatingCashflow":-57252000,"totalDebt":693000,"debtToEquity":1.6,"currentRatio":3.23,"returnOnAssets":-54.2,"returnOnEquity":-102.9,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":7.9,"targetHighPrice":10,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":33.6,"institutionHeldPercent":48,"sharesOutstanding":56521282,"floatShares":13398708,"sharesShort":1134300,"shortRatio":2.75,"shortPercentOfFloat":2,"epsTrailing":-1,"epsForward":-1.1,"revenuePerShare":0,"bookValue":0.68,"officers":[{"age":68,"name":"Dr. Barry D. Quart Pharm.D.","title":"CEO & Director"},{"age":51,"name":"Mr. David L. Szekeres J.D.","title":"President"},{"age":48,"name":"Ms. Lisa  Peraza CPA","title":"Senior Vice President of Finance"},{"age":43,"name":"Mr. Jeff  Cohn J.D.","title":"General Counsel & Corporate Secretary"},{"age":55,"name":"Mr. Sean T. Ristine","title":"Vice President of Human Resources"},{"age":61,"name":"Dr. Lei  Sun Ph.D.","title":"VP of Biologics & Head of CMC"},{"age":null,"name":"Dr. Srikanth  Pendyala M.D.","title":"Senior Vice President of Clinical Development(Consultant)"},{"age":65,"name":"Ms. Kimberly J. Manhard","title":"Executive VP & Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.connectbiopharm.com","phone":"877 245 2787"}}